BioLineRx (BLRX) Common Equity (2024 - 2025)
BioLineRx has reported Common Equity over the past 2 years, most recently at $18.2 million for Q4 2025.
- Quarterly results put Common Equity at $18.2 million for Q4 2025, up 35.18% from a year ago — trailing twelve months through Dec 2025 was $18.2 million (up 35.18% YoY), and the annual figure for FY2025 was $18.2 million, up 35.18%.
- Common Equity for Q4 2025 was $18.2 million at BioLineRx, up from $13.5 million in the prior quarter.
- Over the last five years, Common Equity for BLRX hit a ceiling of $18.2 million in Q4 2025 and a floor of $13.5 million in Q4 2024.